These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36891190)

  • 1. A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer.
    Hofmarcher T; Malmberg C; Lindgren P
    Front Med (Lausanne); 2023; 10():1119506. PubMed ID: 36891190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
    Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
    John A; Shah RA; Wong WB; Schneider CE; Alexander M
    Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.
    Steuten L; Goulart B; Meropol NJ; Pritchard D; Ramsey SD
    JCO Clin Cancer Inform; 2019 Jun; 3():1-10. PubMed ID: 31242043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
    Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
    BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
    Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
    BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
    Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
    Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review.
    Henderson R; Keeling P; French D; Smart D; Sullivan R; Lawler M
    Mol Oncol; 2021 Oct; 15(10):2672-2687. PubMed ID: 34110679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
    PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
    Sadik H; Pritchard D; Keeling DM; Policht F; Riccelli P; Stone G; Finkel K; Schreier J; Munksted S
    JCO Precis Oncol; 2022 Oct; 6():e2200246. PubMed ID: 36315914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    Schluckebier L; Caetano R; Garay OU; Montenegro GT; Custodio M; Aran V; Gil Ferreira C
    BMC Cancer; 2020 Sep; 20(1):875. PubMed ID: 32928143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Moldaver D; Hurry M; Evans WK; Cheema PK; Sangha R; Burkes R; Melosky B; Tran D; Boehm D; Venkatesh J; Walisser S; Orava E; Grima D
    Lung Cancer; 2020 Jan; 139():185-194. PubMed ID: 31812889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.